#Germany #gene therapy #Cell Therapy #Cologne #Cellex

A Company Poised for Growth

Introduction

In the rapidly evolving field of cell and gene therapy (CGT), Cellex Cell Professionals stands out as a leader with over a decade of experience. The company, originally founded in 2001 in Dresden, has significantly expanded its operations, particularly in the last few years. With a reputation for excellence and a focus on operational quality, Cellex continues to deliver high-quality cell and gene therapies.

History and Development

Cellex was established by Prof. Dr. Gerhard Ehninger with the mission of providing safe cellular therapies for patients requiring allogeneic stem cell transplants. Over the years, the company has transitioned into one of Europe’s foremost Contract Development and Manufacturing Organizations (CDMOs) specializing in CGT. Following its expansion into Cologne in 2009 and the opening of a second collection center, Cellex has successfully conducted over 50,000 cell collections.

In 2013, Cellex extended its offerings across the entire value chain, managing the global transport of over 20,000 cell deliveries. The company's growth trajectory continued as it introduced a comprehensive donor database and GMP-grade materials, highlighting its commitment to reliability and quality.

Recent Expansions

Since 2019, Cellex has made three significant expansions to its Good Manufacturing Practice (GMP) infrastructure. These included the creation of high-throughput cleanroom environments and quality control laboratories. The most recent facility expansion now boasts over 2,500 square meters of GMP-certified production space, with 43% allocated to 37 cleanroom workplaces. This expansion underscores Cellex’s capacity to manufacture over 5,800 CGT/ATMP batches, including more than 1,300 clinical and over 4,500 commercial products, demonstrating consistent performance across the development spectrum.

In 2023, Cellex successfully produced the first allogeneic CAR-T product within Europe, marking a significant milestone in its technological advancement. Carla Kreissig, the Managing Director and Chief Medical Officer of Cellex, notes that this achievement reflects the high level of process maturity and confidence from its partners.

Importance of Infrastructure

The establishment of a new storage facility this year, designed to the highest standards, further enhances Cellex's operational capabilities. This facility ensures quality, safety, and efficiency across all batches produced. As demand continues to rise within the CGT sector, Cellex is well-prepared to invest in expanding its infrastructure to meet this growing need.

Strategic Partnerships

Cellex's commitment to collaboration underscores its credibility in the market. The company began its first partnership with a pharmaceutical client in 2017, leading to its first commercial batch delivery in 2023. It also partnered with another pharmaceutical company in 2020, with commercial deliveries expected in 2024. These strategic alliances reflect Cellex’s unique position within the European CDMO landscape, which is enhanced not only by its capabilities but also by its proven track record.

Looking Ahead

As of January 2025, Cellex has secured two new clients, solidifying a robust pipeline of new contracts for the year ahead. With more than a decade of expertise in autologous and allogeneic cell therapies, the company is uniquely positioned to support clients from preclinical development to market launch.

Conclusion

Cellex Cell Professionals continues to set benchmarks in the CGT industry through its advanced facilities, growing partnerships, and commitment to high-quality manufacturing. With its significant expansions and a strong foothold in the European market, Cellex is not just meeting the challenges of today but is also strategically positioned for future opportunities in the rapidly advancing field of cell and gene therapies.

For more information on Cellex Cell Professionals, you can visit Cellex's website.

For media inquiries, please contact:
Phone: +49 221 2509 0
Email: [email protected]